HRP20151382T1 - Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar - Google Patents

Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar Download PDF

Info

Publication number
HRP20151382T1
HRP20151382T1 HRP20151382TT HRP20151382T HRP20151382T1 HR P20151382 T1 HRP20151382 T1 HR P20151382T1 HR P20151382T T HRP20151382T T HR P20151382TT HR P20151382 T HRP20151382 T HR P20151382T HR P20151382 T1 HRP20151382 T1 HR P20151382T1
Authority
HR
Croatia
Prior art keywords
weight
total weight
amount
pharmaceutical preparation
preparation
Prior art date
Application number
HRP20151382TT
Other languages
English (en)
Croatian (hr)
Inventor
Durga Maheswari Parvataneni
Siddhartha YEDLURI
Venkata Satyanarayana APPADWEDULA
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43923331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20151382(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Publication of HRP20151382T1 publication Critical patent/HRP20151382T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HRP20151382TT 2011-03-07 2011-08-10 Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar HRP20151382T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1103860.1A GB2488788B (en) 2011-03-07 2011-03-07 Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
PCT/IB2011/001842 WO2012120328A1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent
EP11764851.9A EP2683381B1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent

Publications (1)

Publication Number Publication Date
HRP20151382T1 true HRP20151382T1 (hr) 2016-02-12

Family

ID=43923331

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151382TT HRP20151382T1 (hr) 2011-03-07 2011-08-10 Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar

Country Status (33)

Country Link
US (1) US9895367B2 (OSRAM)
EP (1) EP2683381B1 (OSRAM)
JP (1) JP5788534B2 (OSRAM)
KR (1) KR101767296B1 (OSRAM)
CN (1) CN103561742B (OSRAM)
AP (1) AP4076A (OSRAM)
AU (1) AU2011361921B2 (OSRAM)
BR (1) BR112013022930A2 (OSRAM)
CA (1) CA2829015C (OSRAM)
CO (1) CO6811851A2 (OSRAM)
CY (1) CY1116968T1 (OSRAM)
DK (1) DK2683381T3 (OSRAM)
EA (1) EA024610B1 (OSRAM)
ES (1) ES2554927T3 (OSRAM)
GB (1) GB2488788B (OSRAM)
GE (1) GEP20156410B (OSRAM)
HR (1) HRP20151382T1 (OSRAM)
HU (1) HUE025562T2 (OSRAM)
IL (1) IL228218A (OSRAM)
MA (1) MA35088B1 (OSRAM)
MX (1) MX339130B (OSRAM)
MY (1) MY158693A (OSRAM)
NZ (1) NZ614903A (OSRAM)
PH (1) PH12013501844A1 (OSRAM)
PL (1) PL2683381T3 (OSRAM)
PT (1) PT2683381E (OSRAM)
RS (1) RS54420B1 (OSRAM)
SG (1) SG193349A1 (OSRAM)
SI (1) SI2683381T1 (OSRAM)
SM (1) SMT201500235B (OSRAM)
UA (1) UA111074C2 (OSRAM)
WO (1) WO2012120328A1 (OSRAM)
ZA (1) ZA201306643B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44079B1 (fr) * 2015-12-18 2021-10-29 Natco Pharma Ltd Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
WO2017115316A1 (en) * 2015-12-29 2017-07-06 Noivita S.R.L.S. Lipophilic formulations
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
CN107564610A (zh) * 2017-10-20 2018-01-09 浙江中大元通特种电缆有限公司 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. PHARMACEUTICAL COMPOSITIONS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
PT999826E (pt) * 1997-07-29 2004-09-30 Upjohn Co Formulacao auto-emulsionante para compostos lipofilos
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
EP1498143A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
HRP20070146B1 (hr) 2004-09-09 2015-12-04 Natco Pharma Limited Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinaze
WO2008057291A2 (en) * 2006-10-26 2008-05-15 Sicor Inc. Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
US7799339B2 (en) * 2007-04-30 2010-09-21 Intezyne Technologies, Inc. Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents
US8067422B2 (en) * 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2009109867A2 (en) 2008-03-04 2009-09-11 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
US20110160249A1 (en) * 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor

Also Published As

Publication number Publication date
MY158693A (en) 2016-11-15
GB2488788B (en) 2013-07-10
US20130338180A1 (en) 2013-12-19
RS54420B1 (sr) 2016-04-28
EA201391280A1 (ru) 2014-02-28
JP2014507463A (ja) 2014-03-27
DK2683381T3 (en) 2015-12-21
AP2013007128A0 (en) 2013-09-30
SG193349A1 (en) 2013-10-30
BR112013022930A2 (pt) 2016-12-06
NZ614903A (en) 2014-08-29
EP2683381A1 (en) 2014-01-15
KR20140016926A (ko) 2014-02-10
PH12013501844A1 (en) 2015-10-23
GEP20156410B (en) 2015-12-10
HUE025562T2 (en) 2016-03-29
AU2011361921A2 (en) 2014-10-30
IL228218A (en) 2016-06-30
CO6811851A2 (es) 2013-12-16
ES2554927T3 (es) 2015-12-28
MX2013010160A (es) 2013-12-06
US9895367B2 (en) 2018-02-20
AP4076A (en) 2017-03-23
CA2829015A1 (en) 2012-09-13
AU2011361921B2 (en) 2016-06-09
MA35088B1 (fr) 2014-05-02
CN103561742A (zh) 2014-02-05
KR101767296B1 (ko) 2017-08-10
MX339130B (es) 2016-05-13
JP5788534B2 (ja) 2015-09-30
CY1116968T1 (el) 2017-04-05
GB201103860D0 (en) 2011-04-20
EP2683381B1 (en) 2015-09-16
PL2683381T3 (pl) 2016-06-30
GB2488788A (en) 2012-09-12
UA111074C2 (uk) 2016-03-25
CA2829015C (en) 2018-01-02
AU2011361921A1 (en) 2013-09-26
CN103561742B (zh) 2016-04-27
ZA201306643B (en) 2014-11-26
WO2012120328A1 (en) 2012-09-13
SI2683381T1 (sl) 2016-01-29
SMT201500235B (it) 2015-10-30
PT2683381E (pt) 2015-11-02
EA024610B1 (ru) 2016-10-31

Similar Documents

Publication Publication Date Title
HRP20151382T1 (hr) Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar
RU2621615C2 (ru) Фармацевтическая композиция, содержащая луликоназол
JP2012524771A5 (OSRAM)
KR102162901B1 (ko) 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법
BRPI0710611A2 (pt) composições farmacêuticas e seus usos
JP2023153863A (ja) 15-hepeを含む組成物及びその使用方法
JP2013100317A5 (OSRAM)
JP2014504259A5 (OSRAM)
RU2015136849A (ru) Композиции, содержащие 15-он эпк, и способы их применения
RU2015131700A (ru) Фармацевтические композиции, включающие производное камптотецина
ES2242061T3 (es) Composicion que comprende paracetamol y un componente de enmascaramiento del amargor.
JP2013515018A5 (OSRAM)
CN111491625B (zh) 溶解尿酸单钠以治疗痛风
JP2015516418A5 (OSRAM)
JP2025061087A (ja) 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法
JP2023518822A (ja) pH依存的再構築が可能な医薬キャリア、その製造方法及び使用方法
RU2020111980A (ru) Фармацевтическая композиция
JP7751969B2 (ja) 外用乳化組成物
JP6900189B2 (ja) 外用組成物
CN111356450A (zh) Pde5抑制剂的液体填充制剂
RU2017137141A (ru) Жидкие концентраты для производства напитков, стабилизированные экстрактом килайи, и способы их приготовления
WO2018123906A1 (ja) 外用組成物
CN115397470A (zh) 具有改善的自愿接受度的组合物
JP2000053562A (ja) 噴射用組成物
ES2406186B1 (es) Emulsiones con derivados alquílicos del dihidroxibenceno.